These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17044439)

  • 1. C-reactive protein and anemia: implications for patients on dialysis.
    Breiterman-White R
    Nephrol Nurs J; 2006; 33(5):555-8. PubMed ID: 17044439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infection and inflammation in patients on dialysis: an underlying contributor to anemia and epoetin alfa hyporesponse.
    Breiterman-White R
    Nephrol Nurs J; 2006; 33(3):319-22; quiz 323-4. PubMed ID: 16859203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing hyporesponse to Epoetin alfa: an algorithm approach: case study of the anemic patient.
    Wingard R
    Nephrol Nurs J; 2000 Oct; 27(5):517-20. PubMed ID: 16649327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timely correction of anemia at the initiation of dialysis. Case study of the anemic patient.
    Breiterman-White R
    Nephrol Nurs J; 2002 Oct; 29(5):469-72. PubMed ID: 12434453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supporting epoetin alfa stimulated erythropoiesis: identifying appropriate iron levels: case study of the anemic patient.
    Sasak C
    Nephrol Nurs J; 2000 Dec; 27(6):612-5. PubMed ID: 16649342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia management practices in peritoneal dialysis patients. Case study of the anemic patient.
    MacCracken MA
    Nephrol Nurs J; 2001 Aug; 28(4):435-8. PubMed ID: 12143466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the anemia of end-stage renal disease after hospitalization.
    Krishnan M; Adams E
    Nephrol Nurs J; 2004; 31(5):541-4. PubMed ID: 15518256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
    Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
    Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
    Easom A
    Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.
    Snaedal S; Heimbürger O; Qureshi AR; Danielsson A; Wikström B; Fellström B; Fehrman-Ekholm I; Carrero JJ; Alvestrand A; Stenvinkel P; Bárány P
    Am J Kidney Dis; 2009 Jun; 53(6):1024-33. PubMed ID: 19394732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
    Larson K
    Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia management protocols: providing consistent hemoglobin outcomes.
    Michael M
    Nephrol Nurs J; 2005; 32(4):423-6. PubMed ID: 16180783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infection and inflammation in dialysis patients: impact on laboratory parameters and anemia. Case study of the anemic patient.
    Szymanski N
    Nephrol Nurs J; 2001 Jun; 28(3):337-40. PubMed ID: 12143455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updating practices in an evolving IV iron and anemia environment: practical solutions.
    Amerling R; Easom A; Juergensen P
    Nephrol Nurs J; 2007; 34(5):533-41; quiz 542-3. PubMed ID: 18041456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
    Besarab A; Dalton CL
    Nephrol Nurs J; 2001 Aug; 28(4):429-34. PubMed ID: 12143465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of inflammation on nutrition, iron status, and erythropoietin responsiveness in ESRD patients.
    Bistrian BR; Carey LA
    Nephrol Nurs J; 2000 Dec; 27(6):616-22. PubMed ID: 16649343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.